antineoplaston a10 has been researched along with Adenocarcinoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Abukhiran, I; Bellizzi, AM; Dunseth, CD; Gosse, MD; Hornick, JL; Humble, RM; Isidro, RA; Pelletier, DJ; Varshney, N | 1 |
| Chen, B; Ren, Y; Xu, F; Zhang, M | 1 |
| Akagi, Y; Araki, Y; Hara, H; Kumabe, T; Matono, K; Ogata, Y; Saitsu, H; Sata, M; Shirouzu, K; Tsuda, H | 1 |
3 other study(ies) available for antineoplaston a10 and Adenocarcinoma
| Article | Year |
|---|---|
Strong Annexin A10 Expression Supports a Pancreatic Primary and Combined Annexin A10, Claudin 18, and SOX2 Expression Supports an Esophagogastric Origin in Carcinomas of Unknown Primary.
Topics: Adenocarcinoma; Annexins; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Cholangiocarcinoma; Claudins; Humans; Neoplasms, Unknown Primary; Pancreatic Neoplasms; SOXB1 Transcription Factors | 2023 |
Comprehensive analysis of the prognosis of S100 family members and their relationship with tumor-infiltrating immune cells in human pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Biomarkers, Tumor; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis | 2023 |
Long-term survival following treatment with antineoplastons for colon cancer with unresectable multiple liver metastases: report of a case.
Topics: Adenocarcinoma; Aged; Benzeneacetamides; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Electrocoagulation; Humans; Liver Neoplasms; Male; Microwaves; Piperidones; Prognosis; Survivors | 2003 |